FMP

FMP

Gilead Sciences (NASDAQ:GILD) Sees Positive Outlook from Morgan Stanley with a New Price Target

-

twitterlinkedinfacebook
blog post cover photo

Image credit: Google Images

Gilead Sciences (NASDAQ:GILD) is a biopharmaceutical company known for its innovative treatments in areas such as HIV, liver diseases, and cancer. The company has a strong presence in the pharmaceutical industry, competing with other major players like Pfizer and Merck. Gilead's stock is currently trading at $108, reflecting its dynamic market activity.

On June 18, 2025, Terence Flynn from Morgan Stanley set a price target of $135 for Gilead, suggesting a potential 25% increase from its current trading price. This optimistic outlook is supported by recent developments, such as the FDA approval of Yeztugo. As highlighted by Morgan Stanley, this approval is seen as a positive step for Gilead, potentially boosting its market position. The approval of Yeztugo is a significant milestone for Gilead, aligning with investor expectations and potentially driving future growth.

This development is expected to enhance Gilead's financial performance, contributing to the company's market capitalization of approximately $134.3 billion. The stock's recent trading range, with a low of $107.2 and a high of $111.78, reflects investor interest in the company's prospects. Gilead's stock has experienced fluctuations over the past year, with a high of $119.96 and a low of $64.86. Despite these variations, the company's strong market position and recent FDA approval provide a solid foundation for future growth. Today's trading volume of 11,816,865 shares indicates active investor engagement, further supporting the positive outlook for Gilead's stock.

Other Blogs

Dec 22, 2024 12:59 PM - Sanzhi Kobzhan

Two great Software Platform Stocks Similar to Palantir (PLTR)

When it comes to cutting-edge software and data analytics, Palantir Technologies (NYSE: PLTR) is often front and center. But for many investors, it’s important to consider alternative or complementary stocks in the same sector that may offer robust growth potential. As PLTR looks expensive (overvalu...

blog post title

Dec 30, 2024 9:32 AM - Sanzhi Kobzhan

Walk Me Through a DCF: A Simple Guide to Discounted Cash Flow Valuation

Are you curious about how professional investors decide whether a stock might be one of the best undervalued stocks to buy now? One of the most popular tools is the Discounted Cash Flow (DCF) model. In this article, I’ll walk you through a DCF step by step. By the end, you’ll see how the Advanced DC...

blog post title

Jan 8, 2025 12:56 PM - Sanzhi Kobzhan

Understanding EPS and How It Helps Investors Find Great Opportunities

Investors often look at a variety of metrics to figure out how well a company is doing. One such important metric is Earnings Per Share (EPS). If you’ve ever wanted to know the eps meaning, here’s a straightforward explanation: EPS shows how much profit a business earns for each of its outstanding s...

blog post title